Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Vujic

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Expert Opinion on Biological Therapy|July 25, 2015
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectivesMartina Sanlorenzo, Igor Vujic, Adrian Moy, et al.
JAMA Dermatology|July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Igor Vujic, Adil Daud, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2016
The burden of malignant melanoma--lessons to be learned from AustriaBabak Monshi, Marin Vujic, Danijel Kivaranovic, et al.
Nanoscale|June 3, 2014
DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeuticsAlfonso Latorre, Christian Posch, Yolanda Garcimartín, et al.
Oncotarget|December 16, 2014
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancerIgor Vujic, Martina Sanlorenzo, Christian Posch, et al.
Oncotarget|January 16, 2016
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsIgor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, et al.
Therapeutic Advances in Chronic Disease|February 13, 2023
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE studyConstanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, et al.
Oncotarget|October 4, 2014
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapiesIgor Vujic, Christian Posch, Martina Sanlorenzo, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaMartina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Expert Opinion on Biological Therapy|July 25, 2015
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectivesMartina Sanlorenzo, Igor Vujic, Adrian Moy, et al.
JAMA Dermatology|July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Igor Vujic, Adil Daud, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2016
The burden of malignant melanoma--lessons to be learned from AustriaBabak Monshi, Marin Vujic, Danijel Kivaranovic, et al.
Nanoscale|June 3, 2014
DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeuticsAlfonso Latorre, Christian Posch, Yolanda Garcimartín, et al.
Oncotarget|December 16, 2014
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancerIgor Vujic, Martina Sanlorenzo, Christian Posch, et al.
Oncotarget|January 16, 2016
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsIgor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, et al.
Therapeutic Advances in Chronic Disease|February 13, 2023
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE studyConstanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, et al.
Oncotarget|October 4, 2014
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapiesIgor Vujic, Christian Posch, Martina Sanlorenzo, et al.
Journal of the American Academy of Dermatology|December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaMartina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Cancer Biology & Therapy|March 22, 2014
Melanoma immunotherapyMartina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Pageof 6